FDA Approves New Cholesterol Drug Enlicitide

The FDA approved a once-daily 20 mg tablet that blocks the PCSK9 protein to lower LDL cholesterol levels in adults.

Updated on Oct. 27, 2026 in Heart Disease

Bold flat-color editorial illustration featuring abstract geometric receptor shapes, representing the function of a new cholesterol-regulating medication. — The FDA approved enlicitide, a new daily 20 mg tablet that manages LDL cholesterol levels by inhibiting the PCSK9 protein in adults. AI Illustration. Upload story photo >

Live Poll

Is now a good time to consider switching your cholesterol medication to a newer alternative?

In July 2026, the FDA approved enlicitide, a new once-daily 20 mg tablet designed to manage cholesterol by inhibiting the PCSK9 protein. This approval follows positive clinical trial results demonstrating significant LDL reductions in adult patients.

Why it matters

By blocking PCSK9, the medication allows the liver to clear more LDL cholesterol from the bloodstream than is typical for many patients. Researchers are currently conducting further studies to determine if this mechanism translates into a reduced risk of strokes and heart attacks.

Clinical trials showed LDL reductions of 57% in the 2,900-person CORALreef Lipids study and 59% in the 303-person CORALreef HeFH trial. Reported side effects in the smaller study included diarrhoea at 7% and dizziness at 9% among participants.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.

The details

Enlicitide functions by binding to the PCSK9 protein, which prevents it from attaching to LDL receptors on the surface of liver cells. By inhibiting this interaction, the drug increases the number of receptors available to remove cholesterol from the body.

The FDA approved the use of enlicitide in July 2026.
LDL reduction was measured at 24 weeks during clinical trials.
Patients in the studies sustained LDL reduction levels for one year.

Health Landscape

The approval of enlicitide follows the data established by the CORALreef Lipids trial regarding its ability to modulate lipid levels. This milestone represents a shift in therapeutic options as researchers continue to examine how PCSK9 inhibition impacts long-term cardiovascular health.

Patients may now have access to a once-daily oral medication to manage cholesterol levels as an alternative to existing treatments. Individuals interested in enlicitide should consult their healthcare provider to discuss potential side effects such as dizziness or gastrointestinal issues.

The takeaway

Enlicitide offers a new oral option for patients struggling to maintain healthy cholesterol levels through traditional methods. Future clinical updates will clarify whether this specific medication effectively lowers the risk of serious heart-related events over time.